ArticleInternational journal of otolaryngology2011
Novel therapeutic strategies for malignant salivary gland tumors: lessons learned from breast cancer.
Article in International journal of otolaryngology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 28 citations in OpenAlex.
- Case Report: Case studies evaluating anti-HER2 therapy as a tumor-agnostic strategy in rare malignancies.Frontiers in oncology · 2026Article
- Immunohistochemical Study of Progesterone Receptor Expression in Pleomorphic Adenoma and Mucoepidermoid Carcinoma of the Salivary Gland.Journal of dentistry (Shiraz, Iran) · 2025Article
- Molecular pathology in breast disease: diagnostic, prognostic, and therapeutic tools.Virchows Archiv : an international journal of pathology · 2024Review
- Clinicopathological correlation of Cathepsin K expression in salivary gland carcinomas; relation to patients` outcome.Diagnostic pathology · 2023Article
- Cimetidine-induced androgenic failure causes cell death and changes in actin, EGF and V-ATPase immunoexpression in rat submandibular glands.Journal of anatomy · 2021Article
- Risk of breast cancer in women after a salivary gland carcinoma or pleomorphic adenoma in the Netherlands.Cancer medicine · 2021Article
- Establishment and genomic characterization of primary salivary duct carcinoma cell line.Oral oncology · 2017Article
- Sex hormones in gender-specific risk for head and neck cancer: A review.Journal of International Society of Preventive & Community Dentistry · 2014Review
- A rare malignancy of the parotid gland in a 13-year-old Taiwanese boy: case report of a mammary analogue secretory carcinoma of the salivary gland with molecular study.Medical molecular morphology · 2014Article
- Secretory carcinoma of salivary gland - A systematic review of pediatric case reports and case series.Journal of oral and maxillofacial pathology : JOMFPReview
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant salivary gland tumors (MSGTs) account for 2-6% of all head and neck cancers. Despite the rarity, MSGTs have been of great interest due to a wide variety of pathological features and high metastasis rates resulting in poor prognosis. Surgical resection followed by radiation therapy represents the main treatment of this malignancy. Adjuvant therapy is reserved for the management of local recurrence, no longer amenable to additional local therapy, and for metastasis. Based on the studies from other types of tumors, particularly breast cancer, the expression and function of sex steroid hormone receptors in cancer have been extensively studied and applied to diagnosis and treatment. Although a number of studies in MSGTs have been published, the rationale for hormone therapy is still controversial due to the disparate results and insufficient number of cases. However, some recent reports have demonstrated that certain salivary gland neoplasms are similar to breast cancer, not only in terms of the pathological features, but also at the molecular level. Here, we shed light on the biological similarity between MSGTs and certain types of breast cancer, and describe the potential use of hormone and additional therapies for MSGTs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.